Biomarker-guided combination treatment for residual multiple sclerosis activity
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple sclerosis (MS).
- You are 18 years or older.
- Your MS disability level falls within EDSS 1.0 to 7.5.
- You must fit either the “progressing” or “residual disability” group based on specific scores over time.
- If you can become pregnant, you must use effective birth control during the study.
- You must be able and willing to follow all study steps and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This study tests if a non-invasive treatment called remote ischemic conditioning can help people with primary progressive multiple sclerosis. You wear a blood pressure cuff on your arm that briefly stops blood flow and then releases it, repeated for several cycles. The goal is to see if this improves walking and other functions.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
This trial tests a new cell therapy called SYS6020 for people with multiple sclerosis that has not improved with standard treatments. The goal is to see if it can slow or stop the disease and improve symptoms.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.